Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer. Sun M, Gu Y, Wang J, Zhang Z, et al. Br J Cancer 2025 Apr 25. doi: 10.1038/s41416-025-03002.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun M, Gu Y, Wang J, Zhang Z, et al. Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer. Br J Cancer 2025 Apr 25. doi: 10.1038/s41416-025-03002.
PMID: 40281303